Dr. Timothy Burns: Precision Lung Cancer Therapy | Ep. 15

In this episode of The Oncology Insights Podcast, I speak with Dr. Timothy Burns, Professor of Medicine at The Ohio State University, about KRAS inhibitors within the evolving spectrum of systemic therapies for Non-Small Cell Lung Cancer (NSCLC). We discuss KRAS mutations, treatment resistance, immunotherapy combinations, biomarker testing, brain metastases, and his journey into lung cancer research. Listen now on all major platforms! *“KRAS mutations represent a major therapeutic target across cancers, creating opportunities for increasingly selective inhibitors designed around specific molecular alterations.”* **Meet the guest:** *Dr. Timothy Burns* is Professor of Medicine at The Ohio State University Comprehensive Cancer Center. With more than 89 publications and NCI R01 funding, his research advances targeted therapies for oncogene-driven NSCLC and brain metastases. He has led multiple clinical trials, including early-phase studies contributing to the approval of the KRAS G12C inhibitor sotorasib. Listen to Dr. Timothy Burns on The Oncology Insights Podcast, available on all major platforms. **Liked this one? Don’t stop now.** Here’s what we think you’ll love! **What you will learn:** - (00:00) Highlight - (01:50) Introduction - (07:30) Targeting KRAS mutations - (11:30) Resistance mechanisms - (15:04) Therapy combinations - (20:50) Brain metastases - (28:53) Future KRAS strategies - (36:17) Closing thoughts **The Oncology Insights Podcast** is trusted and supported by innovative companies like: \- WiseVAs \- Elevate \- Zentrix Insights \- ZentrixOS 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The Oncology Insights Podcast LinkedIn: The Oncology Insights Podcast Instagram: The Oncology Insights Podcast YouTube: The Oncology Insights Podcast Facebook: The Oncology Insights Podcast TikTok: The Oncology Insights Podcast